Drug Trial Radar · NCT03476681
Study of NEO-201 in Solid Tumors Expansion Cohorts
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
121
Planned (sponsor's estimate)
Start
Jan 18, 2019
Primary completion
Jun 17, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Precision Biologics, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg. The Expansion Phase of this study is currently enrolling subjects with non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), cervical and uterine cancers who progressed on front line therapy. Subjects will be treated with NEO-201 at the RP2D (1.5 mg/kg) every 2 weeks in combination with pembrolizumab, given 1 day after the NEO-201, at 400 mg IV every 6 weeks.
Conditions
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Cervical Cancer
- Uterine Cancer
Interventions
NEO-201 in combination with pembrolizumabDrug
NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the safety of the combination of NEO-201 with pembrolizumab the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Time frame: 1.5 years
- Determine Objective Response Rate (either Complete Response or Partial Response) as determined by RECIST v1.1 guidelinesTime frame: 1.5 years
- Determine Progression Free Survival as determined by RECIST v1.1 guidelinesTime frame: 1.5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Institute
Bethesda, Maryland
INOVA Schar Cancer Institute
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.